Malova, E. et al. Transforming patient recruitment in clinical trials: communication training to manage uncertainties about risks and benefits. J. Clin. Transl. Sci. 10, e58 (2026).
Google Scholar
Bennette, C.S. et al. Predicting low accrual in the National Cancer Institute’s cooperative group clinical trials. J. Natl. Cancer Inst. 108, 324 (2016).
Denicoff, A. M. et al. The National Cancer Institute-American Society of Clinical Oncology Cancer trial accrual symposium: summary and recommendations. J. Oncol. Pr. 9, 267–276 (2013).
Jenkins, V. et al. Drivers and barriers to patient participation in RCTs. Br. J. Cancer 108, 1402–1407 (2013).
Google Scholar
Stoffel, E. M., Brand, R. E. & Goggins, M. Pancreatic Cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology 164, 752–765 (2023).
Google Scholar
Matrisian, L. M. & Berlin, J. D. The past, present, and future of pancreatic cancer clinical trials. Am. Soc. Clin. Oncol. Educ. Book 35, e205–e215 (2016).
Google Scholar
Pishvaian, M. J. et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 21, 508–518 (2020).
Google Scholar
Tempero, M. A. et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 19, 439–457 (2021).
Google Scholar
Unger, J. M. et al. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J. Natl. Cancer Inst. 111, 245–255 (2019).
Google Scholar
Unger, J. M. et al. When offered to participate”: a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials. J. Natl. Cancer Inst. 113, 244–257 (2021).
Google Scholar
Meropol, N. J. et al. Barriers to clinical trial participation as perceived by oncologists and patients. J. Natl. Compr. Canc Netw. 5, 655–664 (2007).
Google Scholar
Snyder, R. A. Clinical trial eligibility criteria: a structural barrier to diversity in clinical trial enrollment. J. Clin. Oncol. 40, 2183–2185 (2022).
Google Scholar
Riner, A.N. et al. Call to action: overcoming enrollment disparities in cancer clinical trials with modernized eligibility criteria. JNCI Cancer Spectrum 7, 9 (2023).
Parreco, L. K. et al. Power of an effective clinical conversation: improving accrual onto clinical trials. J. Oncol. Pr. 8, 282–286 (2012).
Galvin, R. et al. Barriers to clinical trial enrollment in patients with pancreatic adenocarcinoma eligible for early-phase clinical trials. Oncology 34, 407–412 (2020).
Google Scholar
Cancer Australia, The National Pancreatic Cancer Roadmap (Roadmap). (Cancer Australia, 2022).
Sohal, D. P. S. et al. Metastatic pancreatic cancer: ASCO guideline update. J. Clin. Oncol. 38, 3217–3230 (2020).
Google Scholar
Maharaj, A. D. et al. The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer. HPB 24, 950–962 (2022).
Google Scholar
Grewal, U. S. et al. Clinical trial participation among patients with pancreatic cancer: a pancreatic cancer action network patient survey. JCO Oncol. Adv. 3, e2500140 (2026).
Pilgrim, C. H. C. et al. Changing patterns of care for pancreas cancer in Victoria: the 2022 Pancreas Tumour Summit. ANZ J. Surg. 93, 2638–2647 (2023).
Google Scholar
Rare Cancers Australia, Maximising rare cancer clinical trials in Australia. (Rare Cancers Australia, 2026).
Health, A.I.o. and Welfare, Cancer in Aboriginal & Torres Strait Islander people of Australia. (AIHW, 2018).
Cunningham, J. & Garvey, G. Are there systematic barriers to participation in cancer treatment trials by Aboriginal and Torres Strait Islander cancer patients in Australia? Australian NewZealand J. Public Health 45, 39–45 (2021).
Kaur, M. et al. Broadening eligibility criteria and diversity among patients for cancer clinical trials. NEJM Evid. 3, EVIDoa2300236 (2024).
Google Scholar
Unger, J. M. et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J. Natl. Cancer Inst. 106, dju002 (2014).
Google Scholar
Herremans, K. M. et al. Diversity and inclusion in pancreatic cancer clinical trials. Gastroenterology 161, 1741–1746.e3 (2021).
Google Scholar
Lichtman, S. M. et al. Modernizing Clinical trial eligibility criteria: recommendations of the american society of clinical oncology-friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities working group. J. Clin. Oncol. 35, 3753–3759 (2017).
Google Scholar
Magnuson, A. et al. Modernizing clinical trial eligibility criteria: recommendations of the ASCO-friends of cancer research performance status work group. Clin. Cancer Res 27, 2424–2429 (2021).
Google Scholar
Spira, A. I. et al. Modernizing clinical trial eligibility criteria: recommendations of the ASCO-friends of cancer research laboratory reference ranges and testing intervals work group. Clin. Cancer Res 27, 2416–2423 (2021).
Google Scholar
Osarogiagbon, R. U. et al. Modernizing clinical trial eligibility criteria: recommendations of the ASCO-friends of cancer research prior therapies work group. Clin. Cancer Res 27, 2408–2415 (2021).
Google Scholar
Harvey, R. D. et al. Modernizing clinical trial eligibility criteria: recommendations of the ASCO-friends of cancer research washout period and concomitant medication work group. Clin. Cancer Res 27, 2400–2407 (2021).
Google Scholar
Dotan, E. et al. The GIANT trial (ECOG-ACRIN EA2186) methods paper: a randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer – defining a new treatment option for older vulnerable patients. J. Geriatr. Oncol. 14, 101474 (2023).
Google Scholar
Dotan, E. et al. A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186. J. Clin. Oncol. 42, 4003–4003 (2024).
Rosso, C. et al. Hereditary cancer clinics improve adherence to NCCN germline testing guidelines for pancreatic cancer. J. Natl. Compr. Canc Netw. 22, 299–305 (2024).
Google Scholar
McKay, O. et al. Endoscopic ultrasound molecular evaluation of pancreatic cancer trial to profile molecular landscape of inoperable pancreatic ductal adenocarcinoma. Endosc. Int. Open 14, a27331068 (2026).
Google Scholar
Farnes, I. et al. Molecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced pancreatic cancer – real world data from the NORPACT-2 study. Scand. J. Gastroenterol. 59, 1093–1096 (2024).
Google Scholar
Snow, S. et al. Barriers and unequal access to timely molecular testing results: addressing the inequities in cancer care delays across Canada. Curr. Oncol. 31, 1359–1375 (2024).
Google Scholar
Ding, D. et al. Challenges of the current precision medicine approach for pancreatic cancer: a single institution experience between 2013 and 2017. Cancer Lett. 497, 221–228 (2021).
Google Scholar
Jhala, N., Petersen, J. & Jhala, D. Molecular tests in pancreatic cancer: critical role of molecular testing, expanding access, and adherence to the NCCN guidelines for pancreatic cancer. J. Natl. Compr. Cancer Netw. 22, 360–362 (2024).
Aguirre, A. J. et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discov. 8, 1096–1111 (2018).
Google Scholar
Zhen, D. B. et al. The role of molecular testing in pancreatic cancer. Ther. Adv. Gastroenterol. 16, 17562848231171456 (2023).
Google Scholar
Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47–52 (2016).
Google Scholar
Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495–501 (2015).
Google Scholar
O’Reilly, E. M. et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N. Engl. J. Med. 395, 325–337 (2026).
Google Scholar
Toledano-Fonseca, M. et al. Unveilling the potential of liquid biopsy in pancreatic cancer for molecular diagnosis and treatment guidance. Crit. Rev. Oncol./Hematol. 212, 104807 (2025).
Google Scholar
Fogel, E. L. et al. A multidisciplinary approach to pancreas cancer in 2016: a review. Official Journal of the American College of Gastroenterology. Am. J. Gastroenterol. 112, 537–554 (2017).
Bournet, B. et al. Molecular endoscopic ultrasound for diagnosis of pancreatic cancer. Cancers 3, 872–882 (2011).
Google Scholar
Iwaya, H. et al. Next-generation sequencing analysis of pancreatic cancer using residual liquid cytology specimens from endoscopic ultrasound-guided fine-needle biopsy: a prospective comparative study with tissue specimens. Diagnostics 13, 1078 (2023).
Mahadevia, H. et al. Circulating tumor DNA and tissue testing for pancreatobiliary tumors. JAMA Netw. Open 8, e2531373–e2531373 (2025).
Google Scholar
Sivapalan, L. et al. Molecular profiling of ctDNA in pancreatic cancer: opportunities and challenges for clinical application. Pancreatology 21, 363–378 (2021).
Google Scholar
Dall, G. et al. Equitable access to genomic molecular testing for Australian cancer patients: insights from the Victorian precision oncology summit. Curr. Oncol. 31, 4519–4530 (2024).
Google Scholar
Lara, P. N. Jr. et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J. Clin. Oncol. 19, 1728–1733 (2001).
Google Scholar
Coffin, T. B. & Kenner, B. J. Challenges in recruitment and retention: leveraging health-related antecedents and information carrier factors to improve patient participation in pancreatic cancer research—a review article. Pancreas 51, 1074–1082 (2022).
Clark, L. T. et al. Increasing diversity in clinical trials: overcoming critical barriers. Curr. Probl. Cardiol. 44, 148–172 (2019).
Google Scholar
Bennett, I. M. et al. Health literacy, health disparities, and sources of health information in U.S. older adults. Orthop. Nurs. 37, 54–65 (2018).
Google Scholar
Nappo, S. A., Iafrate, G. B. & Sanchez, Z. M. Motives for participating in a clinical research trial: a pilot study in Brazil. BMC Public Health 13, 19 (2013).
Google Scholar
Ulrich, C. M. et al. Developing a model of the benefits and burdens of research participation in cancer clinical trials. AJOB Prim. Res 3, 10–23 (2012).
Google Scholar
Lie, M. L. S., Lecouturier, J. & Harding, C. Should I stay or should I go? A qualitative study exploring participation in a urology clinical trial. Int. Urogynecol. J. 30, 9–16 (2019).
Google Scholar
Quinn, G. P. et al. Cancer patients’ fears related to clinical trial participation: a qualitative study. J. Cancer Educ. 27, 257–262 (2012).
Google Scholar
McCann, S. K., Campbell, M. K. & Entwistle, V. A. Reasons for participating in randomised controlled trials: conditional altruism and considerations for self. Trials 11, 31 (2010).
Google Scholar
Locock, L. & Smith, L. Personal benefit, or benefiting others? Deciding whether to take part in clinical trials. Clin. Trials 8, 85–93 (2011).
Google Scholar
Jenkins, V. et al. The attitudes of 1066 patients with cancer towards participation in randomised clinical trials. Br. J. Cancer 103, 1801–1807 (2010).
Google Scholar
Drummond, F. J. et al. Health literacy influences men’s active and passive cancer information seeking. Health Lit. Res. Pr. 3, e147–e160 (2019).
Scanlon, J. K. et al. Predictors of participation in clinical research. Nurs. Res. 70, 289–297 (2021).
Google Scholar
Mainous, A. G. et al. Factors influencing physician referrals of patients to clinical trials. J. Natl. Med. Assoc. 100, 1298–1303 (2008).
Google Scholar
Scharff, D. P. et al. More than Tuskegee: understanding mistrust about research participation. J. Health Care Poor Underserved 21, 879–897 (2010).
Google Scholar
Smirnoff, M. et al. A paradigm for understanding trust and mistrust in medical research: the community VOICES study. AJOB Empir. Bioeth. 9, 39–47 (2018).
Google Scholar
Schwei, R. J. et al. Impact of sociodemographic factors and previous interactions with the health care system on institutional trust in three racial/ethnic groups. Patient Educ. Couns. 96, 333–338 (2014).
Google Scholar
Williams, K., Isaac, L. & LaVeist, T. Mistrust of health care organizations is associated with underutilization of health services. Health Serv. Res. 44, 2093–2105 (2009).
Google Scholar
Penberthy, L. et al. Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment. Clin. Trials 9, 788–797 (2012).
Google Scholar
Kurt, A. et al. Research professionals’ perspectives, barriers, and recommendations regarding minority participation in clinical trials. J. Racial Ethn. Health Disparities 4, 1166–1174 (2017).
Google Scholar
Pallmann, P. et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 16, 29 (2018).
Google Scholar
Lu, C. C. et al. Practical considerations and recommendations for master protocol framework: basket, umbrella and platform trials. Ther. Innov. Regul. Sci. 55, 1145–1154 (2021).
Google Scholar
Rosenzweig, A., Moravek, C. & Matrisian, L. M. More efficient clinical trials in pancreatic cancer: develop better treatment options, faster. J. Cancer Metastasis Treat. 8, 46 (2022).
Bower, P. et al. Interventions to improve recruitment and retention in clinical trials: a survey and workshop to assess current practice and future priorities. Trials 15, 399 (2014).
Google Scholar
Tripepi, M. et al. Telemedicine and pancreatic cancer: a systematic review. Telemed. J. E Health 29, 352–360 (2023).
Google Scholar
Underhill, C. et al. Implementing teletrials to improve equity of access for regional patients with cancer: report from the victorian teletrial collaborative. Asia Pac. J. Clin. Oncol. 22, 50–58 (2026).
Google Scholar
You, K. H. et al. Scoping to analyze oncology trial participation in Australia. Semin. Oncol. 49, 178–181 (2022).
Google Scholar
Unger, J. M., McAneny, B. L. & Osarogiagbon, R. U. Cancer in rural America: Improving access to clinical trials and quality of oncologic care. CA Cancer J. Clin. 75, 341–361 (2025).
Google Scholar
Roberts, N. A. et al. Teletrials, the new norm? Expert recommendations for teletrials into the future: findings from the Clinical Oncology Society of Australia Clinical Trial Research Professionals Group Workshop. Asia-Pac. J. Clin. Oncol. 18, 650–659 (2022).
Google Scholar
Aung, E. et al. The role of telehealth in oncology care: a qualitative exploration of patient and clinician perspectives. Eur. J. Cancer Care (Engl.) 31, e13563 (2022).
Google Scholar
Levesque, J.-F., Harris, M. F. & Russell, G. Patient-centred access to health care: conceptualising access at the interface of health systems and populations. Int. J. Equity Health 12, 18 (2013).
Google Scholar
